相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploration into the opinions of patients with HIV, healthcare professionals and the lay public of the use of microneedles in clinical practice: highlighting the translational potential for their role in HIV infection
Kurtis Moffatt et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2021)
Long-acting drugs and formulations for the treatment and prevention of HIV infection
Charles Flexner et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study
Joseph C. Gathe et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2021)
Long-acting injectable HIV therapies: the next frontier
John Thornhill et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2021)
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
Amy G. Cutrell et al.
AIDS (2021)
Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Daryl Hodge et al.
CLINICAL PHARMACOKINETICS (2021)
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
Jean-Michel Molina et al.
LANCET HIV (2021)
Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
Zach W. Howe et al.
PHARMACOTHERAPY (2021)
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe O. C. Orkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection
Ronald D'Amico et al.
CURRENT OPINION IN HIV AND AIDS (2020)
Long-acting implants to treat and prevent HIV infection
Ethel D. Weld et al.
CURRENT OPINION IN HIV AND AIDS (2020)
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1
Martin Markowitz et al.
CURRENT OPINION IN HIV AND AIDS (2020)
Long-acting injectable cabotegravir for the prevention of HIV infection
Meredith E. Clement et al.
CURRENT OPINION IN HIV AND AIDS (2020)
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review
Anthony T. Podany et al.
CLINICAL PHARMACOKINETICS (2020)
Advances in Long-Acting Agents for the Treatment of HIV Infection
Aadia I. Rana et al.
DRUGS (2020)
The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
Thierry Buclin et al.
FRONTIERS IN PHARMACOLOGY (2020)
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Dirk Schuermann et al.
LANCET HIV (2020)
Effectiveness of vaginal microbicides in preventing HIV transmission
Alfred Musekiwa et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2020)
A year-long extended release nanoformulated cabotegravir prodrug
Tanmay A. Kulkarni et al.
NATURE MATERIALS (2020)
Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
Solange M. Simpson et al.
PHARMACEUTICAL RESEARCH (2020)
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Raphael J. Landovitz et al.
LANCET HIV (2020)
Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs
Dhanashree H. Surve et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study
Christine Tagliaferri Rael et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2020)
Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options
Karine Dube et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
Long-acting antiretroviral therapy
Vicente Soriano et al.
NATURE MATERIALS (2020)
Antibody-based strategies in HIV therapy
Wesley D. Kufel
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T. Overton et al.
LANCET (2020)
Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
Manjula Gunawardana et al.
FRONTIERS IN PHARMACOLOGY (2020)
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
Delphine Sculier et al.
PLOS MEDICINE (2020)
Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data
Kathy K. Byrd et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Potential user interest in new long-acting contraceptives: Results from a mixed methods study in Burkina Faso and Uganda
Rebecca L. Callahan et al.
PLOS ONE (2019)
Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
Leah M. Johnson et al.
PHARMACEUTICS (2019)
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline
Lara Esteves Coelho et al.
LANCET HIV (2019)
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities
Sharon Nachman et al.
LANCET HIV (2019)
Creation of a long-acting rilpivirine prodrug nanoformulation
James R. Hilaire et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
S. Rahima Benhabbour et al.
NATURE COMMUNICATIONS (2019)
Long-Acting HIV Drugs for Treatment and Prevention
Roy M. Gulick et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
LB8. Microarray Patch Delivery of Long-Acting HIV PrEP and Contraception
Annie Rein-Weston et al.
Open Forum Infectious Diseases (2019)
Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
Dario Cattaneo et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis
Charles Flexner et al.
CURRENT OPINION IN HIV AND AIDS (2019)
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
Perrine Courlet et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Tian Zhou et al.
BIOMATERIALS (2018)
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M. Llibre et al.
LANCET (2018)
Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals
Tian Zhou et al.
NANOMEDICINE (2018)
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
Andrea Ries Thurman et al.
PLOS ONE (2018)
Rilpivirine long-acting for the prevention and treatment of HIV infection
Francesca Ferretti et al.
CURRENT OPINION IN HIV AND AIDS (2018)
Antiretroviral implants for treatment and prevention of HIV infection
Charles Flexner
CURRENT OPINION IN HIV AND AIDS (2018)
Treatment and prevention of HIV infection with long-acting antiretrovirals
Laura Benitez-Gutierrez et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis
Corrine Ying Xuan Chua et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Brinda Emu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension
Maeliosa T. C. Mc Crudden et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Ultra-long-acting removable drug delivery system for HIV treatment and prevention
Martina Kovarova et al.
NATURE COMMUNICATIONS (2018)
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals
Manel Aouri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Long-acting injectable ART: next revolution in HIV?
Mark A. Boyd et al.
LANCET (2017)
Long-Acting Antiretrovirals: Where Are We now?
Amesika N. Nyaku et al.
CURRENT HIV/AIDS REPORTS (2017)
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Martin Markowitz et al.
LANCET HIV (2017)
Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam
Melinda J. Reese et al.
XENOBIOTICA (2016)
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
Andrew Owen et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
A. Nel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients
Baralee Punyawudho et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis
Manjula Gunawardana et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
David A. Margolis et al.
LANCET INFECTIOUS DISEASES (2015)
Formulation and pharmacology of long-acting rilpivirine
Peter E. Williams et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Formulation and pharmacology of long-acting cabotegravir
Christine Trezza et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Level of Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy (HAART)
Shilpa Viswanathan et al.
AIDS AND BEHAVIOR (2015)
Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
K. Rivet Amico et al.
CLINICAL INFECTIOUS DISEASES (2014)
A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
A. G. A. Jackson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Pharmacokinetics of the etonogestrel contraceptive implant in obese women
Sara Mornar et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2012)
Androgens and doping tests: genetic variation and pit-falls
Anders Rane et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
J. M. Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adherence to Highly Active Antiretroviral Therapy (HAART): A Meta-Analysis
Carmen Ortego et al.
AIDS AND BEHAVIOR (2011)
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
Hilde Azijn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
Robert M. Grant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
分享论文
